Literature DB >> 11726618

Changes in mRNA levels of the Myoc/Tigr gene in the rat eye after experimental elevation of intraocular pressure or optic nerve transection.

F Ahmed1, M Torrado, E Johnson, J Morrison, S I Tomarev.   

Abstract

PURPOSE: To isolate the rat Myoc/Tigr gene and investigate changes in its expression pattern in normal eyes and in eyes with either pressure-induced optic nerve damage or optic nerve transection.
METHODS: Expression pattern of the rat Myoc/Tigr gene was investigated by Northern blot hybridization. Optic nerve damage and death of ganglion cells in the retina were induced unilaterally, by injection of hypertonic saline solution, episcleral vein cauterization, or optic nerve transection. The levels of mRNA for Myoc/Tigr were compared between several tissues of the control and surgically altered eyes, by using semiquantitative RT-PCR, real-time PCR, and Northern blot analysis.
RESULTS: The rat Myoc/Tigr gene is 10 kb long and contains three exons. Among the eye tissues analyzed, Myoc/Tigr mRNA was detected in the combined tissues of the eye angle, sclera, cornea, retina, and optic nerve head. With pressure-induced optic nerve degeneration, the level of Myoc/Tigr mRNA decreased in the retina and the combined tissues of the eye angle, but increased in the optic nerve head. After optic nerve transection, the level of Myoc/Tigr mRNA increased in the retina, but did not change in the combined tissues of the eye angle.
CONCLUSIONS: The decreased level of Myoc/Tigr mRNA in the retina after induction of elevated intraocular pressure compared with that in the control retina cannot be explained by ganglion cell death alone. Differences in Myoc/Tigr mRNA levels in eye tissues after elevation of intraocular pressure or optic nerve transection may reflect the activation of different signaling pathways involved in regulation of this gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726618

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Neuroprotective effect of latanoprost on rat retinal ganglion cells.

Authors:  Hideyo Kudo; Toru Nakazawa; Masahiko Shimura; Hidetoshi Takahashi; Nobuo Fuse; Kenji Kashiwagi; Makoto Tamai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

Review 2.  Glaucoma-associated myocilin: a better understanding but much more to learn.

Authors:  Zachary T Resch; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2008-08-29       Impact factor: 3.467

3.  Little evidence for association of the glaucoma gene MYOC with open-angle glaucoma.

Authors:  Seongsoo Sohn; Wonhee Hur; Young Ran Choi; Yun Shin Chung; Chang-Seok Ki; Changwon Kee
Journal:  Br J Ophthalmol       Date:  2010-05       Impact factor: 4.638

4.  Genetically increasing Myoc expression supports a necessary pathologic role of abnormal proteins in glaucoma.

Authors:  Douglas B Gould; Laura Miceli-Libby; Olga V Savinova; Mario Torrado; Stanislav I Tomarev; Richard S Smith; Simon W M John
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

5.  Elevated amounts of myocilin in the aqueous humor of transgenic mice cause significant changes in ocular gene expression.

Authors:  Walter Paper; Markus Kroeber; Sebastian Heersink; Dietrich A Stephan; Rudolf Fuchshofer; Paul Russell; Ernst R Tamm
Journal:  Exp Eye Res       Date:  2008-06-17       Impact factor: 3.467

6.  Myocardin mRNA is augmented in the failing myocardium: expression profiling in the porcine model and human dilated cardiomyopathy.

Authors:  Mario Torrado; Eduardo López; Alberto Centeno; Constancio Medrano; Alfonso Castro-Beiras; Alexander T Mikhailov
Journal:  J Mol Med (Berl)       Date:  2003-08-13       Impact factor: 4.599

7.  The expression of myocilin during murine eye development.

Authors:  Carmen Knaupp; Cassandra Flügel-Koch; Andreas Goldwich; Andreas Ohlmann; Ernst R Tamm
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-01-29       Impact factor: 3.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.